The global cell culture media market, valued at USD 4.73 billion in 2023, is poised for substantial growth, projected to expand at a CAGR of 12.54% from 2024 to 2030. This essential component in biopharmaceutical manufacturing, cell culture media, provides the necessary nutrients and growth factors to support the cultivation of cells and microorganisms. The rising demand for biopharmaceuticals, coupled with supportive government policies and increased R&D investments, is driving this market's rapid growth. 

Gather more insights about the market drivers, restrains and growth of the Cell Culture Media Market

The COVID-19 pandemic has accelerated the adoption of well-established cell-based vaccine production technologies. The crisis has sparked scientific advancements, particularly in vaccine development and testing. A prime example is the Vero cell line, derived from African green monkey kidney cells, which has been widely utilized in viral vaccine manufacturing and the development of SARS-CoV variants. Lonza Bioscience's ProVeroTM1 Serum-free Medium, a protein-free, non-animal origin medium, is specifically designed to support the growth of Vero cells and MDCK cells.

Additionally, cell culture-produced AAV vectors have emerged as powerful tools for protein and gene delivery in vaccine production and gene therapy. Key market players are actively expanding their production capabilities to meet increasing demand. In 2021, Sartorius increased its production capacity across all regions to address the surge in demand for its core products and to accommodate the growing needs of customers involved in COVID-19 therapeutics and vaccine development.

Application Segmentation Insights